Skip to main content

Table 5 Univariate linear regression analysis (standardized β coefficient) between the studied genes of tumors of study population of BrCa (N = 206)

From: Profiling the expression of pro-metastatic genes in association with the clinicopathological features of primary breast cancer

 

CTTN (n = 174)

RhoA (n = 205)

ROCK (n = 202)

CLDN-1 (n = 206)

CLDN-2 (n = 110)

CLDN-4 (n = 206)

Total population

CTTN

1

     

RhoA

0.065 (0.395)*

1

    

ROCK

0.170 (0.028)

0.246 (< 0.001)

1

   

CLDN-1

− 0.036 (0.646)

− 0.007 (0.917)

− 0.062 (0.391)

1

  

CLDN-2

0.043 (0.686)

− 0.017 (0.866)

0.237 (0.014)

0.034 (0.727)

1

 

CLDN-4

0.013 (0.868)

0.086 (0.228)

− 0.023 (0.752)

0.411 (< 0.001)

− 0.102 (0.292)

1

ER- and PR ± (n = 23)

CTTN

1

     

RhoA

0.182 (0.465)

1

    

ROCK

0.398 (0.091)

0.397 (0.067)

1

   

CLDN-1

0.198 (0.415)

0.009 (0.967)

− 0.049 (0.832)

1

  

CLDN-2

0.655 (0.029)

− 0.247 (0.465)

− 0.285 (0.396)

− 0.316 (0.344)

1

 

CLDN-4

− 0.027 (0.914)

0.077 (0.748)

0.007 (0.975)

0.095 (0.691)

− 0.366 (0.299)

1

ER + and PR ± (n = 158)

CTTN

1

     

RhoA

0.074 (0.404)

1

    

ROCK

0.128 (0.153)

0.280 (0.001)

1

   

CLDN-1

-0.065 (0.469)

− 0.001 (0.994)

− 0.066 (0.433)

1

  

CLDN-2

0.033 (0.786)

− 0.005 (0.965)

0.267 (0.016)

0.020 (0.858)

1

 

CLDN-4

0.016 (0.859)

0.086 (0.301)

− 0.015 (0.862)

0.451 (< 0.001)

− 0.119 (0.284)

1

ALNM– (n = 64)

      

CTTN

1

     

RhoA

− 0.056 (0.705)

1

    

ROCK

− 0.049 (0.741)

0.233 (0.083)

1

   

CLDN-1

0.070 (0.638)

0.011 (0.932)

− 0.166 (0.217)

1

  

CLDN-2

− 0.041 (0.847)

0.166 (0.382)

0.733 (< 0.001)

− 0.045 (0.810)

1

 

CLDN-4

0.022 (0.882)

0.103 (0.446)

− 0.194 (0.151)

0.522 (< 0.001)

− 0.131 (0.490)

1

ALNM + (n = 120)

CTTN

1

     

RhoA

0.129 (0.204)

1

    

ROCK

0.226 (0.027)

0.311 (0.001)

1

   

CLDN-1

− 0.079 (0.448)

− 0.010 (0.921)

0.040 (0.681)

1

  

CLDN-2

0.121 (0.384)

− 0.160 (0.219)

− 0.098 (0.443)

0.004 (0.976)

1

 

CLDN-4

0.030 (0.769)

0.068 (0.479)

0.029 (0.763)

0.377 (< 0.001)

− 0.028 (0.826)

1

Stage I (n = 55)

CTTN

1

     

RhoA

0.060 (0.710)

1

    

ROCK

0.519 (0.001)

0.252 (0.077)

1

   

CLDN-1

− 0.025 (0.877)

− 0.060 (0.674)

− 0.115 (0.422)

1

  

CLDN-2

− 0.064 (0.766)

0.204 (0.298)

0.741 (< 0.001)

− 0.049 (0.800)

1

 

CLDN-4

0.232 (0.144)

0.039 (0.758)

0.002 (0.990)

0.389 (0.004)

− 0.136 (0.480)

1

Stages II-III (n = 126)

CTTN

1

     

RhoA

0.098 (0.329)

1

    

ROCK

0.069 (0.496)

0.308 (0.001)

1

   

CLDN-1

0.002 (0.980)

0.022 (0.818)

0.002 (0.987)

1

  

CLDN-2

0.130 (0.359)

− 0.163 (0.213)

− 0.130 (0.324)

0.013 (0.923)

1

 

CLDN-4

− 0.052 (0.609)

0.085 (0.375)

− 0.019 (0.842)

0.429 (< 0.001)

− 0.014 (0.917)

1

  1. The statistically significant finding is shown in italics (P < 0.05)
  2. N number, CTTN cortactin, RhoA ras homolog gene family member A, ROCK rho-associated kinase, CLDN claudin, ER estrogen receptor, PR progesterone receptor, ALNM axillary lymph node metastasis
  3. *Data were expressed as standardized β coefficient (P-value)